Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
NMYC
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "NMYC" in MCE Product Catalog:
5
5 Cited Publications
Cat. No.: HY-N2068
CAS No.: 14259-47-3
Category:
Flavonoids Monophenols Flavonones Rutaceae Phenols Plants Disease Research Fields Citrus Cancer
Target:
2
2 Cited Publications
EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis .
2
2 Cited Publications
VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel (HY-B0015) resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer) .
1
1 Cited Publications
Research Areas:
DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research .
Cat. No.: HY-168439
CAS No.: 2566733-45-5
Target:
Research Areas:
HLB-0532259 is a PROTAC degrader for Aurora-A and N-Myc. HLB-0532259 degrades Aurora-Ain a non-MYCN amplified MCF-7 with a DC50 of 20.2 nM, degrades N-Myc in MYCN amplified cells SK-N-BE and Kelly with DC50 of 179 nM and 229 nM. HLB-0532259 exhibits antitumor efficacy in mouse models .
Cat. No.: HY-171770
CAS No.: 3115765-45-9
Research Areas:
dAurAB5 is a dual Aurora-A (DC50 = 8.8 nM) and Aurora-B (DC50 = 6.1 nM) PROTAC degrader. dAurAB5 induces degradation of Aurora-A and Aurora-B, reduces N-Myc levels, and decreases viability in IMR32 neuroblastoma cells. dAurAB5 downregulates the levels of AAK1, PTK2, GAK, and TTK. dAurAB5 can be used to study cancers such as neuroblastoma. (Pink: TTK ligand 2: HY-168542, Blue: Thalidomide-O-COOH: HY-103597, Black: 6-Aminocaproic acid: HY-B0236) .
Cat. No.: HY-171769
CAS No.: 3115765-38-0
Target:
Research Areas:
dAurAB2 is a dual-degrading PROTAC that potently degrades Aurora-A and Aurora-B with DC50s of 59 nM and 39 nM, respectively. dAurAB2 reduces N-Myc levels in MYCN-amplified IMR32 neuroblastoma cells. dAurAB2 can be used for the study of neuroblastoma. (Pink, Aurora ligand (HY-10804); Blue, E3 ligand: (HY-103597); Black, linker (HY-W105740)) .
Cat. No.: HY-162470
CAS No.: 2702965-64-6
Target:
Research Areas:
DBPR728 is an acyl prodrug of 6K465 that carries fewer hydrogen bond donors. 6K465 acts as an Aurora kinase inhibitor that destabilizes MYC family cancer proteins and has antitumor efficacy. DBPR728 has the potential to inhibit cancers that overexpress C-MYC and N-MYC, with a 10-fold increase in oral bioavailability compared to 6K465 .
Cat. No.: HY-162469
CAS No.: 2702965-27-1
Target:
Research Areas:
6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of c-MYC and N-MYC oncoproteins, demonstrating anticancer activity .
Cat. No.: HY-125090
CAS No.: 398493-74-8
Research Areas:
PHA-680626 is an effective inhibitor of the interaction between Aurora-A and N-Myc. PHA-680626 inhibits kinase activity of AURKA and Bcr-Abl, and induces N-Myc degradation. PHA-680626 decreases phosphorylation of CrkL and histone H3. PHA-680626 shows anti-proliferative and pro-apoptotic activity on Imatinib (HY-15463)-resistant chronic myeloid leukemia cell lines and primary CD34+ cells .
Cat. No.: HY-RS17293
Target:
Research Areas:
Mycn Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mycn gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08884
Target:
Research Areas:
MYCN Human Pre-designed siRNA Set A contains three designed siRNAs for MYCN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-N2068R
CAS No.: 14259-47-3
Category:
Flavonoids Monophenols Flavonones Rutaceae Phenols Plants Citrus
Target:
Cat. No.: HY-115832
CAS No.: 79514-49-1
Target:
Research Areas:
Ap44mSe is a selenosemicarbazone that effectively depletes cellular Fe, resulting in transferrin receptor-1 up-regulation, ferritin down-regulation, and increased expression of the potent metastasis suppressor, N-myc downstream regulated gene-1. Ap44mSe forms redox active Cu complexes that target the lysosome to induce lysosomal membrane permeabilization .
Cat. No.: HY-RS23748
Target:
Research Areas:
Mycn Rat Pre-designed siRNA Set A contains three designed siRNAs for Mycn gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P790041
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Nmi; N-myc and STAT interactor
Cat. No.: HY-P702776
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: bHLHe37; Class E basic helix-loop-helix protein 37; MODED; mycn; Oncogene NMYC; pp65/67
Species:
Source:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
